Maximum Strength Pepcid AC Approval Calls For Postmarketing Study
This article was originally published in The Tan Sheet
Executive Summary
Johnson & Johnson/Merck is required to submit a protocol by late March 2004 for a postmarket study on Pepcid AC (famotidine) (10 mg) and new Maximum Strength Pepcid AC (20 mg), following FDA approval of the latter Sept. 24
You may also be interested in...
Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts
The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.
Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts
The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.
Canada Trims Red Tape Around OTC Switches As Part Of Agency Cuts
The process of switching drugs Rx-to-OTC will be streamlined as part of the government’s budget cuts. Health Canada, which must save $200 million annually by fiscal year 2014-15, also is tweaking its regulation of natural health products.